CDKN2B-AS1 as a novel therapeutic target in cancer: Mechanism and clinical perspective

Ahmed Hjazi; Eishah Ghaffar; Waqas Asghar; Hasan Alauldeen Khalaf; Muhammad Ikram Ullah; Rosario Mireya Romero-Parra; Beneen M Hussien; Adeeb Abdulally Abdulhussien Alazbjee; Yashwant Singh Bisht; Yasser Fakri Mustafa; Seyed Reza Hosseini-Fard

doi:10.1016/j.bcp.2023.115627

CDKN2B-AS1 as a novel therapeutic target in cancer: Mechanism and clinical perspective

Biochem Pharmacol. 2023 Jul:213:115627. doi: 10.1016/j.bcp.2023.115627. Epub 2023 May 29.

Affiliations

¹ Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
² Fatima Jinnah Medical University, Lahore, Pakistan.
³ Rai Medical College Sargodha, Pakistan.
⁴ College of Pharmacy, Al-Bayan University, Baghdad, Iraq.
⁵ Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Sakaka 75471, Aljouf, Saudi Arabia.
⁶ Universidad Continental. Lima, Perú. Electronic address: [email protected].
⁷ Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.
⁸ Collage of Medicin, Al-Ayen University, Thi-Qar, Iraq.
⁹ Uttaranchal Institute of Technology, Uttaranchal University, Dehradun 248007, India.
¹⁰ Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul 41001, Iraq.
¹¹ Biochemistry Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

PMID: 37257723
DOI: 10.1016/j.bcp.2023.115627

Abstract

Long non-coding RNAs (lncRNA) have been identified as essential components having considerable modulatory impactson biological activities through altering gene transcription, epigenetic changes, and protein translation. Cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1), a recently discovered lncRNA, was shown to be substantially elevated in various cancers.Furthermore, via modulation ofvarious signalingaxes, it is effectively connected to the control of critical cancer-associatedbiological pathways likecell proliferation, apoptosis, cell cycle, epithelial-mesenchymal transition(EMT), invasion, and migration. Considering the crucial functions ofCDKN2B-AS1in cancer onset and development, this lncRNA offers immense therapeutic implications for usage as a new diagnostic or treatment approach. In this article, we evaluate the most recent discoveries made into the functions of the lncRNA CDKN2B-AS1 in cancer, in addition to its prospect asbeneficial properties,prognostic anddiagnostic biomarkersin the cancer-related treatment, emphasizingits participation in a broad network of signalingaxes whichcould affectvariouscancers and investigating its promising therapeutic possibility.

Keywords: CDKN2B-AS1; Cancer; LncRNA; NcRNA.

Publication types

Review

MeSH terms

Cell Line, Tumor
Cell Movement / genetics
Cell Proliferation / genetics
Gene Expression Regulation, Neoplastic
Humans
MicroRNAs* / genetics
Neoplasms* / drug therapy
Neoplasms* / genetics
Prognosis
RNA, Antisense
RNA, Long Noncoding* / genetics
RNA, Long Noncoding* / metabolism

Substances

MicroRNAs
RNA, Antisense
RNA, Long Noncoding
CDKN2B antisense RNA, human